Comparison of cardioprotective effects of salvianolic acid B and benazepril on large myocardial infarction in rats

Pharmacological Reports

Volumn 60, Issue 3, 2008, Pages 369-381

  He, Hai Bo ^a   Yang, Xian Zhe ^a   Shi, Meng Qiong ^b   Zeng, Xiao Wei ^a   Wu, Li Mao ^a   Li, Lian Da ^a  

^a ZHEJIANG UNIVERSITY   (China)

^b Center of Medical Sciences Analysis   (China)

Author keywords

Angiogenesis; Benazepril; Blood viscosity; Heart function; Infarct size; Large myocardial infarction; Salvianolic acid B; Ventricular remodeling

Indexed keywords

BENAZEPRIL; MESSENGER RNA; SALVIANOLIC ACID B; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD RHEOLOGY; BLOOD VISCOSITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG MECHANISM; ECHOCARDIOGRAPHY; HEART DILATATION; HEART HEMODYNAMICS; HEART HYPERTROPHY; HEART INFARCTION; HEART INFARCTION SIZE; HEART LEFT VENTRICLE DILATATION; HEART MUSCLE FIBROSIS; HEART PROTECTION; HEART VENTRICLE REMODELING; MALE; MICROCIRCULATION; NONHUMAN; PROTEIN EXPRESSION; RAT;

EID: 49349102936     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: None     Document Type: Article

References (36)

1. Feng Y, Dai DZ, Na T, Cui B, Wang T, Zhang Y, Dai Y: Endothelin receptor antagonist CPU0213 suppresses ventricular fibrillation in 1-thyroxin induced cardiomyopathy. Pharmacol Rep, 2007, 59, 1734-1140.
2. Fishbein MC, Maclean D, Maroko PR: Experimental myocardial infarction in the rat: qualitative and quantitative changes during pathologic evolution. Am J Pathol, 1978, 90, 57-70.
3. Folkinan J: Seminars in medicine of the Beth Israel hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med, 1995, 333, 1757-1763.
4. Freedman SB, Isner JM: Therapeutic angiogenesis for ischemic cardiovascular disease. J Mol Cell Cardiol, 2001, 33, 379-393.
5. Griendling KK, Sorescu D, Ushio-Fukai M: NAD(P)H oxidase: role in cardiovascular biology and disease. Circ Res, 2000, 86, 494-501.
6. He HB, Yu F, Dai DZ, Dai Y: Down-regulation of FKBP 12.6 and SERCA2a contributes to acute heart failure in septic shock and is related to an up-regulated endothelin signaling pathway. J Pharm Pharmacol, 2007, 59, 977-984.
7. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ, Shah PK et al.: The VIVA trial: vascular endothelial growth factor in ischemia for vascular angiogenesis. Circulation, 2003, 107, 1359-1365.
8. Ikeda S, Ushio-Fukai M, Zoo L, Tojo T, Alexander RW: Novel role of ARF6 in vascular endothclial growth factor signaling and angiogenesis. Circ Res, 2005, 96, 467-475.
9. Ji XY, Tan BK, Zhu YC, Linz W, Zhu YZ: Comparison of cardioprotective effects using ramipril and DanShen for the treatment of acute myocardial infarction in rats. Life Sci, 2003, 73, 1413-1426.
10. 165 gene therapy in patients with stable severe angina pectoris A randomized double-blind ptacebo-controlled study: the Euroinject One trial. J Am Coll Cardiol, 2005, 45, 982-988.
11. Lay IS, Chin JH, Shiao MS, Lui WY, Wu CW: Crude extract of Salvia miltiorrhiza and salvianolic acid B enhance in vitro angiogenesis in murine SVR endothelial cell line. Planta Med, 2003, 69, 26-32.
12. Lin YL, Wu CH, Luo ME, Huang YJ, Wang CN, Shiao MS, Huang YT: In vitro protective effects of salvianolic acid B on primary hepatocytes and hepatic stellate cells. J Ethnopharmacol, 2006, 105, 215-222.
13. Liu JX, Li XZ, Ma XB, Lin CR, Wang YH, Ma XY, Wang M: Cardio-protective effects of Corocalm on acute myocardial ischemia/reperfusion injury in rats. Chin J Integr Med, 2006, 12, 199-202.
14. Matsumoto T, Claesson-Welsh L: VEGF receptor signal transduction. Sci STKE, 2001, 112, RE21.
15. Morgan EE, Faulx MD, McElfresh TA, Kung TA, Zawaneh MS, Stanley WC, Chandler MP, Hoit BD: Validation of echocardiographic; methods for assessing left ventricular dysfunction in rats with myocardial infarction. Am J Physiol Heart Circ Physiol, 2004, 287, H2049-H2053.
16. Na T, Dai DZ, Tang XY, Dai Y: Upregulation of leptin pathway correlates with abnormal expression of SERCA2a, phospholamban and the endothelin pathway in heart failure and reversal by CPU86017. Naunyn Schmiedebergs Arch Pharmacol, 2007, 375, 39-49.
17. Nagaya N, Uematsu M, Kojima M, Ikeda Y, Yoshihara F, Shimizu W, Hosoda H et al.: Chronic administration of ghrelin improves left ventricular dysfunction and attenuates development of cardiac cachexia in rats with heart failure. Circulation, 2001, 104, 1430-1435.
18. Nicosia RF, Nicosia SV, Smith M: Vascular endothelial growth factor, platelet-derived growth factor, and insulin-like growth factor-1 promote rat aortic angiogenesis in vitro. Am J Pathol, 1994, 145, 1023-1039.
19. Pearlman JD, Hibberd MG, Chuang ML, Harada K, Lopez JJ, Gladston SR, Friedman M et al.: Magnetic resonance mapping demonstrates benefits of VEGF-induced myocardial angiogenesis. Nat Med, 1995, 1, 1085-1089.
20. Pfeffer MA, Braunwald E, Moye LA, Basta L, Brown EJ Jr, Cuddy TE, Davis BR et al.: Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. N Engl J Med, 1992, 327, 669-677.
21. Sasaki H, Fukuda S, Otani H, Zhu L, Yamaura G, Engelman RM, Das DK, Maulik N: Hypoxic preconditioning triggers myocardial angiogenesis: a novel approach to enhance contractile functional reserve in rat with myocardial infarction. J Mol Cell Cardiol, 2002, 34, 335-348.
22. Soeki T, Kishimoto I, Okumura H, Tokudome T, Horio T, Mori K, Kangawa K: C-type natriuretic peptide, a novel antifibrotic and antihypertrophic agent, prevents cardiac remodeling after myocardial infarction. J Am Coll Cardiol, 2005, 45, 608-616.
23. Stanton LW, Garrard LJ, Damin D, Garrick BL, Lam A, Kapoun AM, Zheng Q et al.: Altered patterns of gene expression in response to myocardial infarction. Circ Res, 2000, 86, 939-945.
24. Stauss HM, Zhu YC, Redlich T, Adamiak D, Mott A, Kregel KC, Unger T: Angiotensin-converting enzyme inhibition in infarct-induced heart failure in rats: bradykinin versus angiotensin II. J Cardiovasc Risk, 1994, 1, 255-262.
25. Sun J, Huang SH, Tan BKH, Whiteman M, Zhu YC, Wu YJ, Ng Y et al.: Effects of purified herbal extract of Salvia miltiorrhiza on ischemic rat myocardium after acute myocardial infarction. Life Sci, 2005, 76, 2849-2860.
26. Ushio-Fukai M: Redox signaling in angiogenesis: role of NADPH oxidase. Cardiovasc; Res, 2006, 71, 226-235.
27. Ushio-Fukai M: VEGF Signaling through NADPH oxidase-derived ROS. Antioxid Redox Signal, 2007, 9, 731-739.
28. Wang XB, Morris-Natschke SL, Lee KH: New developments in the chemistry and biology of the bioactive constituents of Tanshen. Med Res Rev, 2007, 27, 133-148.
29. Wang YQ, Shi YP, Dai DZ: Therapeutic effects of CPU 86017 on acute and chronic congestive cardiac failure mediated by reducing ET-1, NOS and oxidative stress in rats. Drug Dev Res, 2004, 63, 22-32.
30. Wu GF, Du ZM, Hu CH, Zheng ZS, Zhan CY, Ma H, Fang DQ et al.: Angiogenic effects of long-term enhanced external counterpulsation in a dog model of myocardial infarction. Am J Physiol Heart Circ Physiol, 2006, 290, H248-H254.
31. Zhang HS, Wang SQ: Salvianolic acid B from Salvia miltiorrhiza inhibitors tumor necrosis factor-α (TNF-α)-induced MMP-2 upregulation in human aortic smooth muscle cells via suppression of NAD(P)H oxidase-derived reactive oxygen species. J Mol Cell Cardiol, 2006, 41, 138-148.
32. Zhang SY, Chen SL, Shen YJ, Yang DJ, Liu XJ, Sun-Chi AC, Xu H: Puerarin induces angiogenesis in myocardium of rat with myocardial infarction. Biol Pharm Bull, 2006, 29, 945-950.
33. Zhao BL, Jiang W, Zhao Y, Hou JW, Xin WJ: Scavenging effects of Salvia miltiorrhiza on free radicals and its protection for myocardial mitochondrial membranes from ischemia-reperfusion injury. Biochem Mol Biol Int, 1996, 38, 1171-1182.
34. Zhou L, Chow MS, Zuo Z: Improved quality control method for Danshen products - consideration of both hydrophilic and lipophilic active components. J Pharm Biomed Anal, 2006, 41, 744-750.
35. Zhu YC, Zhu YZ, Gohlke P, Stauss HM, Unger T: Effects of angiotensin-coverting enzyme inhibition and angiotensin II AT1 receptor antagonism on cardiac parameters in left ventricular hypertrophy. Am J Cardiol, 1997, 80, 110A-117A.
36. Zhu YZ, Zhu YC, Golke P, Unger T: Overview on pharmacological properties of angiotensin coverting enzyme inhibitors. In: ACE Inhibition and Target Organ Protection. Ed. Hall AS, Unger T, Euromed Communications Ltd., Oxford, UK, 1998, 1-20.